Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH
Webinar scheduled for Thursday, November 17, 2022 , at 11:00 a.m. EST Featuring key opinion leader discussion on current treatment landscape NEW YORK , Nov. 9, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company
